HuGE Literature Finder
Records 1-15
|
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
|
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
The pharmacogenomics journal 2018 01 18 (1): 35-42. Li M, Seiser E L, Baldwin R M, Ramirez J, Ratain M J, Innocenti F, Kroetz D |
|
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Leukemia & lymphoma 2016 Oct 1-10. Megías-Vericat Juan Eduardo, Montesinos Pau, Herrero María José, Moscardó Federico, Bosó Virginia, Rojas Luis, Martínez-Cuadrón David, Hervás David, Boluda Blanca, García-Robles Ana, Rodríguez-Veiga Rebeca, Martín-Cerezuela María, Cervera José, Sendra Luis, Sanz Jaime, Miguel Antonio, Lorenzo Ignacio, Poveda José Luis, Sanz Miguel Ángel, Aliño Salvador |
|
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Pharmacogenetics and genomics 2015 Sep . Chen Sylvia, Villeneuve Lyne, Jonker Derek, Couture Félix, Laverdière Isabelle, Cecchin Erica, Innocenti Federico, Toffoli Giuseppe, Lévesque Eric, Guillemette Chant |
|
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
|
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
PloS one 2015 10 (8): e0134102. Chu Ying-Hsia, Li Huihua, Tan Hui Shan, Koh Valerie, Lai Johnathan, Phyo Wai Min, Choudhury Yukti, Kanesvaran Ravindran, Chau Noan Minh, Toh Chee Keong, Ng Quan Sing, Tan Puay Hoon, Chowbay Balram, Tan Min-H |
|
Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.
Oncology letters 2014 Jun 7 (6): 2035-2040. Moriya Hiroyuki, Saito Katsuhiko, Helsby Nuala, Sugino Shigekazu, Yamakage Michiaki, Sawaguchi Takeru, Takasaki Masahiko, Kato Hidenori, Kurosawa Naho |
|
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Pharmacogenomics 2014 15 (12): 1565-74. Lamba Jatinder Kaur, Fridley Brooke L, Ghosh Taraswi M, Yu Qing, Mehta Gaurav, Gupta Pank |
|
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Cancer chemotherapy and pharmacology 2013 Oct 72 (4): 825-35. Kim Hye Ryun, Park Hyung Soon, Kwon Woo Sun, Lee Ji Hyun, Tanigawara Yusuke, Lim Sun Min, Kim Hyo Song, Shin Sang Jun, Ahn Jung Bae, Rha Sun You |
|
Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Omics : a journal of integrative biology 2013 Jul 17 (7): 353-67. Awada Zainab, Haider Syed, Tfayli Arafat, Bazarbachi Ali, El-Saghir Nagi S, Salem Ziad, Shamseddine Ali, Taher Ali, Zgheib Nathalie Khouei |
|
[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2013 Jun 16 (6): 524-8. Sun Zhi-wei, Wang Xi-cheng, Gao Jing, Li Jie, Li Yan-yan, Dang Yun-zhi, Shen L |
|
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Investigational new drugs 2011 Oct 29 (5): 953-62. Steeghs Neeltje, Mathijssen Ron H J, Wessels Judith A M, de Graan Anne-Joy, van der Straaten Tahar, Mariani Mariangela, Laffranchi Bernard, Comis Silvia, de Jonge Maja J A, Gelderblom Hans, Guchelaar Henk-J |
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Cancer chemotherapy and pharmacology 2010 May 66 (1): 95-105. Sai Kimie, Saito Yoshiro, Maekawa Keiko, Kim Su-Ryang, Kaniwa Nahoko, Nishimaki-Mogami Tomoko, Sawada Jun-ichi, Shirao Kuniaki, Hamaguchi Tetsuya, Yamamoto Noboru, Kunitoh Hideo, Ohe Yuichiro, Yamada Yasuhide, Tamura Tomohide, Yoshida Teruhiko, Matsumura Yasuhiro, Ohtsu Atsushi, Saijo Nagahiro, Minami Hirono |
|
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Cancer science 2007 Sep 98 (9): 1461-7. Jada Srinivasa Rao, Lim Robert, Wong Chiung Ing, Shu Xiaochen, Lee Soo Chin, Zhou Qingyu, Goh Boon Cher, Chowbay Balr |
|
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Cancer 2007 Jul 110 (1): 138-47. Han Ji-Youn, Lim Hyeong-Seok, Yoo Yeon-Kyeong, Shin Eun Soon, Park Yong Hoon, Lee Sung Young, Lee Jong-Eun, Lee Dea Ho, Kim Heung Tae, Lee Jin S |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: